Fabrication and characterisation of lavender oil - plant phospholipid based Sumatriptan succinate hybrid solid lipid nanoparticles.

• Main Authors: Reeta (Author), Rashid Mehmood (Author), Maria John Newton Amaldoss (Author)
• Format: Book
• Published: Mazandaran University of Medical Sciences, 2020-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2423-4494
• Keywords: nanostructured lipid carriers (nlcs); zetasizer; zeta potential; transmission electron microscopy (tem); Therapeutics. Pharmacology; RM1-950
• Source: Pharmaceutical and Biomedical Research, Vol 6, Iss 1, Pp 91-104 (2020)

Background: Nanostructured lipid carriers (NLCs) of sumatriptan succinate (SS) were prepared by using lavender oil. In ancient days, lavender oil was used for the treatment of a migraine. The natural anti-migraine agent, lavender oil, combined with an anti-migraine drug such as SS in a nano-formulation, will be a practical alternative approach in migraine therapy. Objective: NLCs of sumatriptan succinate were fabricated by using a natural anti-migraine oil (lavender oil), LECIVA-S70, which is a specialized grade for liposomal dermatological preparation and designed for emulsion, fat infusions, nutraceutical formulations, and parenteral use. It contains 70% phosphatidylcholine, which is not generally present in the regular soy lecithin. Methods: The central composite design technique was used to examine the relationship between independent variables and responses such as lavender oil and LECIVA-S70. The dependent variables were Z-average (R1), polydispersity index (R2), and % entrapment efficiency (R3). The NLCs were prepared with the double emulsification technique. The Fourier transform infrared spectroscopy, X-ray diffraction, and differential scanning calorimetry analyzed the drug excipient compatibility profile. The developed NLCs were characterized for particle size by using Mastersizer, Zetasizer, and transmission electron microscopy. The membrane diffusion technique studied the in vitro drug release profile. Results: The mean±SD size of the NLCs ranged from 411.4±311.1 d.nm to 398.8±242.6 d.nm. The best formulation (SNE9) demonstrated an average diameter of 398.8±242.6 d.nm, with the PDI of 0.216, and zeta potential of 17.18 mV. Conclusion: The optimized formula demonstrated the narrow size range, a satisfactory zeta potential, high drug loading, and reproducible drug release profile. The NLCs successfully retained the aroma of the lavender oil. According to ANOVA, the polydispersity index (R2) is significant with the central composite design.